RPG Life Sciences Limited has released its Annual Report for FY 2025-26, highlighting resilient financial performance, strong domestic formulations growth, and continued progress on its strategic transformation agenda. The company reported total income of ₹733.06 crores on a standalone basis for the year ended March 31, 2026, compared to ₹666.11 crores in the previous year, driven primarily by improved performance in the Domestic Formulations business. The Nineteenth Annual General Meeting (AGM) is scheduled for Thursday, July 23, 2026, at 3.00 p.m. (IST) through Video Conferencing/Other Audio-Visual Means.

Financial Performance Overview

The company delivered revenues of ₹707.5 crores during FY26, registering a growth of 8.3%, while maintaining healthy EBITDA margins of 24.4%. The balance sheet remained strong with healthy cash reserves of approximately ₹275 crores. The following table summarises key standalone financial results:

On a consolidated basis, the company reported total income of ₹733.10 crores and profit before exceptional items and tax of ₹150.30 crores for the year. Exceptional items for FY 2025-26 totalled ₹390 crores (net), comprising a net insurance income of ₹2,475 crores related to the fire incident at the API plant, partially offset by the impact of new Labour Codes (₹1,169 crores) and write-off of intangible assets under development (₹916 crores).

Key Financial Highlights (Five-Year Trend)

The company's five-year financial trajectory reflects consistent growth across key metrics:

Segment-wise Performance

The company operates across three business segments—Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients (API).

Domestic Formulations contributed 69% of total revenue and outperformed the Indian Pharmaceutical Market (IPM) across all four quarters of FY26. While IPM grew by 8.6%, the Domestic Formulations business delivered growth of 13.7%, approximately 1.6x faster than the market. The company emerged as the 4th fastest-growing pharmaceutical company among the Top 50 pharma companies in Q4 FY26 and advanced its IPM ranking by 6 positions during FY26. Within the specialty portfolio, Nephrology grew by 55.2%, Rheumatology by 40.2%, Oncology by 23.2%, and Pain management by 19.8%. The flagship brand "Naprosyn" recorded market-beating growth of 15.6% and is progressing towards becoming the company's first ₹100 crores brand.

International Formulations registered a de-growth of 6.7% due to inventory norms rationalisation. The business has a presence across geographies including UK, Australia, Canada, Myanmar, Germany, Colombia, Philippines, Vietnam, Mauritius, Chile, South Africa, and Kenya, among others. The company received product approvals in UAE, Bolivia, and Guatemala, and received approval for an Abbreviated New Drug Submission (ANDS) from Health Canada for Naproxen 220 mg.

API achieved sales of ₹95.06 crores, growing 5.3% over the previous year. The API plant is now fully operational following restoration and validation activities post the fire incident. Key APIs include Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, and Lercanidipine.

Dividend and Key Ratios

The Board has recommended a final dividend of ₹24 per equity share (300% on the face value of ₹8 each) for FY 2025-26, subject to shareholder approval at the Nineteenth Annual General Meeting. Key financial ratios for the year are summarised below:

The company's ICRA long-term rating was reaffirmed at [ICRA] A+ (Stable) and the short-term rating at [ICRA] A1 during the year.

Operational and Strategic Highlights

Sales force productivity improved to ₹6.5 lakhs per representative per month, up from ₹5.7 lakhs in the previous year, while specialty productivity improved significantly to ₹16.7 lakhs. The company's proprietary doctor engagement platform, "RPGServ", now supports engagement with over 1,00,000 doctors, including more than 36,000 specialists across multiple therapy areas.

Manufacturing facilities continued to scale capabilities, supported by regulatory approvals including EU GMP (Hamburg Health Authority, Germany), TGA Australia, and PMDA Japan GMP certifications. The company also signed a Power Purchase Agreement for supply of Solar Power at its API Plant in Navi Mumbai as part of its energy conservation initiatives. Energy conservation measures during the year contributed to a reduction in the cost of production by ₹195.79 lakhs.

The company invested ₹34.77 crores in the equity share capital of RPG Active Pharma Limited, a wholly owned subsidiary incorporated on December 24, 2025. Total R&D expenditure for the year stood at ₹984 lakhs, representing 1.39% of total turnover.

AGM and Corporate Governance

The Nineteenth Annual General Meeting is scheduled for Thursday, July 23, 2026, at 3.00 p.m. (IST) through Video Conferencing/Other Audio-Visual Means. The record date for determining dividend entitlement has been fixed as Thursday, July 9, 2026. Remote e-voting will be open from Monday, July 20, 2026 at 09:00 a.m. to Wednesday, July 22, 2026 at 05:00 p.m. Key AGM agenda items include adoption of audited financial statements, declaration of dividend, re-appointment of Mr. Harsh V. Goenka and Mr. Manoj Maheshwari as directors retiring by rotation, appointment of Dr. Pratit Samdani as Independent Director for a term of five consecutive years from April 29, 2026 to April 28, 2031, and ratification of remuneration payable to M/s. Kirit Mehta & Co. as Cost Auditors for FY 2026-27.

CSR and Sustainability

The company contributed ₹243 lakhs to RPG Foundation towards CSR activities during FY 2025-26, covering education, heritage preservation, and community development initiatives. The total CSR obligation for the year was ₹243 lakhs, which was spent in entirety. Foreign exchange earned in terms of actual inflows was ₹19,555 lakhs, while foreign exchange outgo in terms of actual outflow was ₹3,204 lakhs.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE105J01010/6e99b307-136c-4bb6-95e1-c0c9bfa46652.pdf

RPG Life Sciences Limited has fixed Thursday, July 9, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹24 per share for the financial year ended March 31, 2026. The dividend, recommended by the Board at its meeting on April 29, 2026, is subject to approval by shareholders at the Nineteenth Annual General Meeting (AGM) scheduled for Thursday, July 23, 2026. The payment will be made within 30 days of the AGM to members whose names appear in the Register of Members or the depositories' records on the record date.

The company communicated this decision to the National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The AGM will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM) at 3.00 p.m. (IST).

Rajesh Shirambekar, Head – Legal & Company Secretary, signed the regulatory filing confirming the schedule. The company has requested the exchanges to take the information on record. The Notice of AGM, containing further relevant details, will be issued in due course.